ICU · cardiovascular
Acute Severe Pulmonary Embolism — Comprehensive ICU Management
Also known as Pulmonary embolism · PE · Massive PE · Submassive PE · Pulmonary embolism with shock · Thrombolysis for PE · Pulmonary embolectomy · PERT
Acute severe pulmonary embolism (PE) — obstruction of the pulmonary arterial tree by thrombus (usually from deep vein thrombosis) causing increased dead space, right ventricular afterload, RV failure, reduced cardiac output, and potentially cardiac arrest. Risk factors: immobility, malignancy, surgery, pregnancy, OCP, inherited thrombophilia (factor V Leiden, prothrombin gene mutation, antithrombin deficiency). Severity classification: massive PE (high-risk — sustained hypotension, cardiogenic shock, or cardiac arrest — registry mortality 25 per cent in shock, 65 per cent with CPR), submassive PE (intermediate-risk — normotensive but RV strain — RV dysfunction on echo + biomarker elevation; death or decompensation 5.6 per cent at 7 days on heparin alone in PEITHO), low-risk PE (sPESI 0 — 30-day mortality 1.0 per cent). ICU management: massive PE → thrombolysis (alteplase 100 mg IV over 2 h, run with heparin as in the landmark trial) OR catheter-directed thrombolysis OR surgical embolectomy; thrombolysis during CPR for PE-arrest (tenecteplase 50 mg IV bolus reported with neurological recovery); submassive PE → anticoagulation + monitor for deterioration (rescue thrombolysis only if decompensates — PEITHO showed routine lysis adds stroke and bleeding without a mortality benefit); low-risk → anticoagulation + consider early discharge. VA-ECMO for refractory collapse (bridge to definitive therapy). PESI/sPESI guide disposition. Chronic thromboembolic pulmonary hypertension develops in 3.8 per cent of survivors by two years.
Checked against its sources on 3 Sept 2026
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Massive PE: sustained hypotension, cardiogenic shock, or cardiac arrest → give alteplase 100 mg IV over 2 h IMMEDIATELY (do NOT wait for CTPA if clinical suspicion is high and the patient is crashing)
- RV strain on echo (regional RV dysfunction with mid-free-wall akinesia and apical sparing — McConnell sign) in a normotensive patient = submassive PE = intermediate risk — monitor closely for haemodynamic deterioration
- ECG: S1Q3T3 (sensitive only in the textbooks — 6 per cent in one community series), sinus tachycardia, right axis deviation, right bundle branch block, T-wave inversion V1-V4 (anteroseptal) — PE pattern
- Cardiac arrest with PEA + venous thrombosis risk factors = consider massive PE → give thrombolysis during CPR without stopping compressions (tenecteplase 50 mg IV bolus reported with ROSC at 13 minutes and intact neurological recovery)
- Contrast CT for diagnosis is DANGEROUS in an unstable patient — in the major-PE registry, definitive imaging was obtained in only 32 per cent of patients presenting in circulatory collapse → if PE is suspected and the patient is crashing → DO NOT send to CT → treat on clinical suspicion + bedside echo (RV strain)
Meet the patient
A 58-year-old man, three weeks out from a total hip replacement, is brought in blue: GCS 14, SBP 76, HR 132, RR 32, SpO2 88% on 15 L via a non-rebreather. His JVP is up to the ear, the lung fields are clear, and the ECG shows sinus tachycardia with an S1Q3T3 pattern. Bedside echo shows a dilated right ventricle with a D-shaped septum and a plethoric, non-collapsing IVC. You are not sending him to CT.[1]
Two questions decide his next hour, and they are the two that decide every severe PE: is he haemodynamically crashing? (the cuff pressure answers immediately) and is there RV strain? (the bedside echo answers in 60 seconds). A crashing patient with RV strain gets alteplase on clinical grounds — in the multicentre major-PE registry, echocardiography was the most frequently performed diagnostic test (74 per cent), and definitive lung imaging was obtained in only 32 per cent of patients presenting in circulatory collapse. The scanner is for the patients who can survive the trip down the corridor.[1][4]
References20ShowHide
- [1]Konstantinides Stavros V, Meyer Guy, Becattini Cecilia, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) Eur Heart J, 2020.PMID 31504429
- [2]Konstantinides Stavros, Geibel Annette, Heusel Gerhard, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism N Engl J Med, 2002.PMID 12374874
- [3]Meyer Guy, Vicaut Eric, Danays Thierry, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism N Engl J Med, 2014.PMID 24716681
- [4]Kasper W, Konstantinides S, Geibel A Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry J Am Coll Cardiol, 1997.PMID 9350909
- [5]Raschke R A, Reilly B M, Guidry J R The weight-based heparin dosing nomogram compared with a 'standard care' nomogram. A randomized controlled trial Ann Intern Med, 1993.PMID 8214998
- [6]McConnell M V, Solomon S D, Rayan M E Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism Am J Cardiol, 1996.PMID 8752195
- [7]Jiménez David, Aujesky Drahomir, Moores Lisa, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism Arch Intern Med, 2010.PMID 20696966
- [8]Lankeit Mareike, Jiménez David, Kostrubiec Maciej Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study Circulation, 2011.PMID 22082681
- [9]Righini Marc, Van Es Josien, Den Exter Paul L Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study JAMA, 2014.PMID 24643601
- [10]Agnelli Giancarlo, Buller Harry R, Cohen Alexander, et al. Oral apixaban for the treatment of acute venous thromboembolism N Engl J Med, 2013.PMID 23808982
- [11]Büller Harry R, Prins Martin H, Lensin Anthonie W A, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med, 2012.PMID 22449293
- [12]Agnelli Giancarlo, Becattini Cecilia, Meyer Guy, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer N Engl J Med, 2020.PMID 32223112
- [13]Pengo Vittorio, Denas Gentian, Zoppellaro Giacomo Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome Blood, 2018.PMID 30002145
- [14]Kucher Nils, Boekstegers Peter, Müller Oliver J Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism Circulation, 2014.PMID 24226805
- [15]Piazza Gregory, Hohlfelder Benjamin, Jaff Michael R, et al. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study JACC Cardiovasc Interv, 2015.PMID 26315743
- [16]Perrott Jerrold, Henneberry Ryan J, Zed Peter J Thrombolytics for cardiac arrest: case report and systematic review of controlled trials Ann Pharmacother, 2010.PMID 21119096
- [17]Pengo Vittorio, Lensing Anthonie W A, Prins Martin H, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism N Engl J Med, 2004.PMID 15163775
- [18]Goldhaber S Z, Visani L, De Rosa M Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) Lancet, 1999.PMID 10227218
- [19]Mismetti Patrick, Laporte Silvy, Pellerin Olivier, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial JAMA, 2015.PMID 25919526
- [20]Bajaj Navin, Bozarth Andrew L, Guillot Juan Clinical features in patients with pulmonary embolism at a community hospital: analysis of 4 years of data J Thromb Thrombolysis, 2014.PMID 23681675